{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:45:50Z","timestamp":1790484350411,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The University Synergy Innovation Program of Anhui Province","award":["GXXT-2021-064"],"award-info":[{"award-number":["GXXT-2021-064"]}]},{"name":"The Enhancement Programme for Basic and Clinical Cooperative Research of Anhui Medical University","award":["2019xkjT016"],"award-info":[{"award-number":["2019xkjT016"]}]},{"name":"The joint project of nephrology and pharmacology at anhui medical university","award":["2021CXK012"],"award-info":[{"award-number":["2021CXK012"]}]},{"name":"The Key Project Foundation of Natural Science Research in Universities of Anhui Province in China","award":["KJ2021A0329"],"award-info":[{"award-number":["KJ2021A0329"]}]},{"name":"The Foundation of Anhui Medical University","award":["2018xkj065"],"award-info":[{"award-number":["2018xkj065"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40264-022-01181-4","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T04:26:06Z","timestamp":1654057566000},"page":"703-712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Incidence, Pathogenesis, and Management of Proton Pump Inhibitor-Induced Nephrotoxicity"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2732-2670","authenticated-orcid":false,"given":"Xiao","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengkun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"issue":"6","key":"1181_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/sj.ki.5002038","volume":"71","author":"UC Brewster","year":"2007","unstructured":"Brewster UC, Perazella MA. Acute kidney injury following proton pump inhibitor therapy. Kidney Int. 2007;71(6):589\u201393.","journal-title":"Kidney Int"},{"issue":"17","key":"1181_CR2","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999\u20132012. JAMA. 2015;314(17):1818\u201331.","journal-title":"JAMA"},{"issue":"7634","key":"1181_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bmj.39406.449456.BE","volume":"336","author":"I Forgacs","year":"2008","unstructured":"Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2\u20133.","journal-title":"BMJ"},{"issue":"1","key":"1181_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s11096-019-00955-8","volume":"42","author":"O Sattayalertyanyong","year":"2020","unstructured":"Sattayalertyanyong O, Thitilertdecha P, Auesomwang C. The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study. Int J Clin Pharm. 2020;42(1):174\u201383.","journal-title":"Int J Clin Pharm"},{"issue":"11","key":"1181_CR5","first-page":"652","volume":"107","author":"E Villamanan","year":"2015","unstructured":"Villamanan E, Ruano M, Lara C, Suarez-de-Parga JM, Armada E, Alvarez-Sala R, et al. Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care. Rev Esp Enferm Dig. 2015;107(11):652\u20138.","journal-title":"Rev Esp Enferm Dig"},{"key":"1181_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejim.2016.10.007","volume":"37","author":"V Savarino","year":"2017","unstructured":"Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19\u201324.","journal-title":"Eur J Intern Med"},{"issue":"20","key":"1181_CR7","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.3390\/ijms20205203","volume":"20","author":"R Fossmark","year":"2019","unstructured":"Fossmark R, Martinsen TC, Waldum HL. Adverse effects of proton pump inhibitors: evidence and plausibility. Int J Mol Sci. 2019;20(20):5203.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1181_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238\u201346.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"1181_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5500\/wjt.v9.i2.35","volume":"9","author":"B Boonpheng","year":"2019","unstructured":"Boonpheng B, Thongprayoon C, Bathini T, Sharma K, Mao MA, Cheungpasitporn W. Proton pump inhibitors and adverse effects in kidney transplant recipients: a meta-analysis. World J Transplant. 2019;9(2):35\u201347.","journal-title":"World J Transplant"},{"issue":"2","key":"1181_CR10","doi-asserted-by":"publisher","first-page":"E166","DOI":"10.9778\/cmajo.20140074","volume":"3","author":"T Antoniou","year":"2015","unstructured":"Antoniou T, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Garg AX, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015;3(2):E166\u201371.","journal-title":"CMAJ Open"},{"issue":"4","key":"1181_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.ajkd.2019.07.012","volume":"75","author":"Z Al-Aly","year":"2020","unstructured":"Al-Aly Z, Maddukuri G, Xie Y. Proton pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to deprescribe. Am J Kidney Dis. 2020;75(4):497\u2013507.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1181_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/0002-9343(92)90181-A","volume":"93","author":"SJ Ruffenach","year":"1992","unstructured":"Ruffenach SJ, Siskind MS, Lien YH. Acute interstitial nephritis due to omeprazole. Am J Med. 1992;93(4):472\u20133.","journal-title":"Am J Med"},{"issue":"10","key":"1181_CR13","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1681\/ASN.2015121377","volume":"27","author":"Y Xie","year":"2016","unstructured":"Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"1181_CR14","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.3748\/wjg.v25.i22.2706","volume":"25","author":"G Bruno","year":"2019","unstructured":"Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, et al. Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified. World J Gastroenterol. 2019;25(22):2706\u201319.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"1181_CR15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrgastro.2017.117","volume":"14","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697\u2013710.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"1181_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1440-1797.2006.00651.x","volume":"11","author":"IJ Simpson","year":"2006","unstructured":"Simpson IJ, Marshall MR, Pilmore H, Manley P, Williams L, Thein H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton). 2006;11(5):381\u20135.","journal-title":"Nephrology (Carlton)"},{"issue":"4","key":"1181_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/ki.2014.74","volume":"86","author":"ML Blank","year":"2014","unstructured":"Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case\u2013control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837\u201344.","journal-title":"Kidney Int"},{"issue":"6","key":"1181_CR18","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2125.2007.02927.x","volume":"64","author":"L Harmark","year":"2007","unstructured":"Harmark L, van der Wiel HE, de Groot MC, van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol. 2007;64(6):819\u201323.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1181_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4103\/0971-4065.114487","volume":"23","author":"K Sampathkumar","year":"2013","unstructured":"Sampathkumar K, Ramalingam R, Prabakar A, Abraham A. Acute interstitial nephritis due to proton pump inhibitors. Indian J Nephrol. 2013;23(4):304\u20137.","journal-title":"Indian J Nephrol."},{"issue":"4","key":"1181_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1053\/j.ajkd.2014.04.027","volume":"64","author":"AK Muriithi","year":"2014","unstructured":"Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME, et al. Biopsy-proven acute interstitial nephritis, 1993\u20132011: a case series. Am J Kidney Dis. 2014;64(4):558\u201366.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1181_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40620-016-0309-2","volume":"29","author":"DG Moledina","year":"2016","unstructured":"Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. J Nephrol. 2016;29(5):611\u20136.","journal-title":"J Nephrol"},{"issue":"2","key":"1181_CR22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1046\/j.1523-1755.2001.060002804.x","volume":"60","author":"J Rossert","year":"2001","unstructured":"Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60(2):804\u201317.","journal-title":"Kidney Int"},{"issue":"3","key":"1181_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1046\/j.1523-1755.2002.00232.x","volume":"61","author":"FB Gabbai","year":"2002","unstructured":"Gabbai FB, Hammond TC, Thomson SC, Khang S, Kelly CJ. Effect of acute iNOS inhibition on glomerular function in tubulointerstitial nephritis. Kidney Int. 2002;61(3):851\u20134.","journal-title":"Kidney Int"},{"issue":"12","key":"1181_CR24","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1111\/j.1572-0241.2001.05345.x","volume":"96","author":"RP Myers","year":"2001","unstructured":"Myers RP, McLaughlin K, Hollomby DJ. Acute interstitial nephritis due to omeprazole. Am J Gastroenterol. 2001;96(12):3428\u201331.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1181_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.ackd.2016.08.003","volume":"24","author":"MA Perazella","year":"2017","unstructured":"Perazella MA. Clinical approach to diagnosing acute and chronic tubulointerstitial disease. Adv Chronic Kidney Dis. 2017;24(2):57\u201363.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"1181_CR26","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/ki.2014.294","volume":"87","author":"AK Muriithi","year":"2015","unstructured":"Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME, et al. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int. 2015;87(2):458\u201364.","journal-title":"Kidney Int"},{"issue":"1","key":"1181_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1440-1797.2005.00365.x","volume":"10","author":"N Geevasinga","year":"2005","unstructured":"Geevasinga N, Coleman PL, Roger SD. Rabeprazole-induced acute interstitial nephritis. Nephrology (Carlton). 2005;10(1):7\u20139.","journal-title":"Nephrology (Carlton)"},{"issue":"8921","key":"1181_CR28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(94)91945-3","volume":"344","author":"M Assouad","year":"1994","unstructured":"Assouad M, Vicks SL, Pokroy MV, Willcourt RJ. Recurrent acute interstitial nephritis on rechallenge with omeprazole. Lancet. 1994;344(8921):549.","journal-title":"Lancet"},{"issue":"5","key":"1181_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cgh.2005.11.004","volume":"4","author":"N Geevasinga","year":"2006","unstructured":"Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol. 2006;4(5):597\u2013604.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"1181_CR30","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.2215\/CJN.07630717","volume":"12","author":"DG Moledina","year":"2017","unstructured":"Moledina DG, Perazella MA. Drug-induced acute interstitial nephritis. Clin J Am Soc Nephrol. 2017;12(12):2046\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1181_CR31","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/ndt\/gfh137","volume":"19","author":"N Torpey","year":"2004","unstructured":"Torpey N, Barker T, Ross C. Drug-induced tubulo-interstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit. Nephrol Dial Transplant. 2004;19(6):1441\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"1181_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4412","volume":"341","author":"S Ray","year":"2010","unstructured":"Ray S, Delaney M, Muller AF. Proton pump inhibitors and acute interstitial nephritis. BMJ. 2010;341: c4412.","journal-title":"BMJ"},{"issue":"2","key":"1181_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol. 2020;31(2):435\u201346.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"1181_CR34","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","volume":"14","author":"H Seethapathy","year":"2019","unstructured":"Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(12):1692\u2013700.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1181_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041543","volume":"11","author":"K Ikuta","year":"2021","unstructured":"Ikuta K, Nakagawa S, Momo K, Yonezawa A, Itohara K, Sato Y, et al. Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case\u2013control study. BMJ Open. 2021;11(2): e041543.","journal-title":"BMJ Open"},{"issue":"10","key":"1181_CR36","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2217\/cer-2019-0017","volume":"8","author":"SS Sutton","year":"2019","unstructured":"Sutton SS, Magagnoli J, Cummings TH, Hardin JW. Risk of acute kidney injury in patients with HIV receiving proton pump inhibitors. J Comp Eff Res. 2019;8(10):781\u201390.","journal-title":"J Comp Eff Res."},{"issue":"8","key":"1181_CR37","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s40264-018-0663-1","volume":"41","author":"H Svanstrom","year":"2018","unstructured":"Svanstrom H, Lund M, Melbye M, Pasternak B. Use of proton pump inhibitors and the risk of acute kidney injury among patients with rheumatoid arthritis: cohort study. Drug Saf. 2018;41(8):817\u201326.","journal-title":"Drug Saf"},{"issue":"1","key":"1181_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/pds.5101","volume":"30","author":"BB Gerstman","year":"2021","unstructured":"Gerstman BB. Proton pump inhibitors and chronic kidney disease: reevaluating the evidence from a randomized controlled trial. Pharmacoepidemiol Drug Saf. 2021;30(1):4\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1181_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1214243","volume":"371","author":"LS Chawla","year":"2014","unstructured":"Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58\u201366.","journal-title":"N Engl J Med"},{"issue":"10212","key":"1181_CR40","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(19)32563-2","volume":"394","author":"C Ronco","year":"2019","unstructured":"Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394(10212):1949\u201364.","journal-title":"Lancet"},{"issue":"4","key":"1181_CR41","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1053\/j.gastro.2017.07.055","volume":"154","author":"M Rudler","year":"2018","unstructured":"Rudler M, Isnard Bagnis C, Rudler H. Proton pump inhibitors and chronic kidney disease: is it related to the accumulation of toxic breakdown products spontaneously formed in the enteric-protected tablets? Gastroenterology. 2018;154(4):1204\u20135.","journal-title":"Gastroenterology"},{"issue":"1","key":"1181_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2131\/jts.23.53","volume":"23","author":"Y Kawasaki","year":"1998","unstructured":"Kawasaki Y, Umemura T, Saito M, Momma J, Matsushima Y, Sekiguchi H, et al. Toxicity study of a rubber antioxidant, 2-mercaptobenzimidazole, by repeated oral administration to rats. J Toxicol Sci. 1998;23(1):53\u201368.","journal-title":"J Toxicol Sci"},{"issue":"8","key":"1181_CR43","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.113.003602","volume":"128","author":"YT Ghebremariam","year":"2013","unstructured":"Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845\u201353.","journal-title":"Circulation"},{"issue":"3","key":"1181_CR44","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","volume":"153","author":"DCF Klatte","year":"2017","unstructured":"Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702\u201310.","journal-title":"Gastroenterology"},{"issue":"4","key":"1181_CR45","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/phar.2235","volume":"39","author":"E Hart","year":"2019","unstructured":"Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy. 2019;39(4):443\u201353.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"1181_CR46","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MNH.0000000000000406","volume":"27","author":"T Li","year":"2018","unstructured":"Li T, Xie Y, Al-Aly Z. The association of proton pump inhibitors and chronic kidney disease: cause or confounding? Curr Opin Nephrol Hypertens. 2018;27(3):182\u20137.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"10","key":"1181_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204231","volume":"13","author":"A Rodriguez-Poncelas","year":"2018","unstructured":"Rodriguez-Poncelas A, Barcelo MA, Saez M, Coll-de-Tuero G. Duration and dosing of proton pump inhibitors associated with high incidence of chronic kidney disease in population-based cohort. PLoS ONE. 2018;13(10): e0204231.","journal-title":"PLoS ONE"},{"issue":"3","key":"1181_CR48","doi-asserted-by":"publisher","first-page":"e0229344","DOI":"10.1371\/journal.pone.0229344","volume":"15","author":"JVM Guedes","year":"2020","unstructured":"Guedes JVM, Aquino JA, Castro TLB, Augusto de Morais F, Baldoni AO, Belo VS, et al. Omeprazole use and risk of chronic kidney disease evolution. PLoS ONE. 2020;15(3):e0229344.","journal-title":"PLoS ONE"},{"issue":"4","key":"1181_CR49","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/j.jrn.2016.11.004","volume":"27","author":"B Haring","year":"2017","unstructured":"Haring B, Selvin E, Liang M, Coresh J, Grams ME, Petruski-Ivleva N, et al. Dietary protein sources and risk for incident chronic kidney disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Ren Nutr. 2017;27(4):233\u201342.","journal-title":"J Ren Nutr"},{"issue":"7","key":"1181_CR50","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/dote.12384","volume":"29","author":"I Mone","year":"2016","unstructured":"Mone I, Kraja B, Bregu A, Duraj V, Sadiku E, Hyska J, et al. Adherence to a predominantly Mediterranean diet decreases the risk of gastroesophageal reflux disease: a cross-sectional study in a South Eastern European population. Dis Esophagus. 2016;29(7):794\u2013800.","journal-title":"Dis Esophagus"},{"issue":"2","key":"1181_CR51","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4103\/0974-777X.112288","volume":"5","author":"RS Mhaskar","year":"2013","unstructured":"Mhaskar RS, Ricardo I, Azliyati A, Laxminarayan R, Amol B, Santosh W, et al. Assessment of risk factors of Helicobacter pylori infection and peptic ulcer disease. J Glob Infect Dis. 2013;5(2):60\u20137.","journal-title":"J Glob Infect Dis."},{"issue":"6","key":"1181_CR52","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1001\/jamainternmed.2016.1845","volume":"176","author":"M Fusaro","year":"2016","unstructured":"Fusaro M, Giannini S, Gallieni M. Adverse effects of proton pump inhibitors in chronic kidney disease. JAMA Intern Med. 2016;176(6):866.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"1181_CR53","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/jcph.672","volume":"56","author":"JH William","year":"2016","unstructured":"William JH, Danziger J. Magnesium deficiency and proton-pump inhibitor use: a clinical review. J Clin Pharmacol. 2016;56(6):660\u20138.","journal-title":"J Clin Pharmacol"},{"key":"1181_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e8525","volume":"346","author":"F Lapi","year":"2013","unstructured":"Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case\u2013control study. BMJ. 2013;346: e8525.","journal-title":"BMJ"},{"issue":"6","key":"1181_CR55","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1053\/j.jrn.2020.11.006","volume":"31","author":"Y Saka","year":"2021","unstructured":"Saka Y, Naruse T, Matsumoto J, Takeda Y, Onogi C, Yokoi J, et al. Low serum zinc concentration is associated with infection particularly in patients with stage 5 chronic kidney disease medicated with proton pump inhibitors. J Ren Nutr. 2021;31(6):579\u201385.","journal-title":"J Ren Nutr"},{"key":"1181_CR56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.diabres.2018.11.019","volume":"147","author":"H Yang","year":"2019","unstructured":"Yang H, Juang SY, Liao KF. Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients. Diabetes Res Clin Pract. 2019;147:67\u201375.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1181_CR57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11920-011-0248-5","volume":"14","author":"NV Halen","year":"2012","unstructured":"Halen NV, Cukor D, Constantiner M, Kimmel PL. Depression and mortality in end-stage renal disease. Curr Psychiatry Rep. 2012;14(1):36\u201344.","journal-title":"Curr Psychiatry Rep"},{"issue":"2","key":"1181_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003546","volume":"18","author":"E Ku","year":"2021","unstructured":"Ku E, Hsu RK, Johansen KL, McCulloch CE, Mitsnefes M, Grimes BA, et al. Recovery of kidney function after dialysis initiation in children and adults in the US: a retrospective study of United States Renal Data System data. PLoS Med. 2021;18(2): e1003546.","journal-title":"PLoS Med"},{"issue":"15","key":"1181_CR59","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003363","volume":"95","author":"YC Peng","year":"2016","unstructured":"Peng YC, Lin CL, Yeh HZ, Chang CS, Wu YL, Kao CH. Association between the use of proton pump inhibitors and the risk of ESRD in renal diseases: a population-based, case\u2013control study. Medicine (Baltimore). 2016;95(15): e3363.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"1181_CR60","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/0018578719894704","volume":"56","author":"A Mertz","year":"2021","unstructured":"Mertz A, Cooney D, Rahman M, Lacey C, Burant CJ, Desai N. Discontinuation of proton pump inhibitors in patients with chronic kidney disease. Hosp Pharm. 2021;56(4):308\u201313.","journal-title":"Hosp Pharm"},{"issue":"1","key":"1181_CR61","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/ki.2013.327","volume":"85","author":"Y Sakaguchi","year":"2014","unstructured":"Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int. 2014;85(1):174\u201381.","journal-title":"Kidney Int"},{"issue":"6","key":"1181_CR62","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1053\/j.ajkd.2015.05.024","volume":"66","author":"L Li","year":"2015","unstructured":"Li L, Streja E, Rhee CM, Mehrotra R, Soohoo M, Brunelli SM, et al. Hypomagnesemia and mortality in incident hemodialysis Patients. Am J Kidney Dis. 2015;66(6):1047\u201355.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1181_CR63","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1053\/j.ajkd.2015.06.014","volume":"66","author":"E Lacson Jr","year":"2015","unstructured":"Lacson E Jr, Wang W, Ma L, Passlick-Deetjen J. Serum magnesium and mortality in hemodialysis patients in the United States: a cohort study. Am J Kidney Dis. 2015;66(6):1056\u201366.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1181_CR64","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5414\/CNP68065","volume":"68","author":"UC Brewster","year":"2007","unstructured":"Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol. 2007;68(2):65\u201372.","journal-title":"Clin Nephrol"},{"issue":"3","key":"1181_CR65","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000360011","volume":"39","author":"M Alhosaini","year":"2014","unstructured":"Alhosaini M, Walter JS, Singh S, Dieter RS, Hsieh A, Leehey DJ. Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors. Am J Nephrol. 2014;39(3):204\u20139.","journal-title":"Am J Nephrol"},{"issue":"12","key":"1181_CR66","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/nep.12330","volume":"19","author":"JH William","year":"2014","unstructured":"William JH, Nelson R, Hayman N, Mukamal KJ, Danziger J. Proton-pump inhibitor use is associated with lower urinary magnesium excretion. Nephrology (Carlton). 2014;19(12):798\u2013801.","journal-title":"Nephrology (Carlton)"},{"issue":"7","key":"1181_CR67","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2337\/dc12-0226","volume":"35","author":"Y Sakaguchi","year":"2012","unstructured":"Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, et al. Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care. 2012;35(7):1591\u20137.","journal-title":"Diabetes Care"},{"issue":"07","key":"1181_CR68","first-page":"594","volume":"21","author":"XX Chen","year":"2021","unstructured":"Chen XX, Zhang L, Wang Y, Zheng JG. Pathological mechanisms of hypomagnesemia aggravating cardiovascular calcification in patients with chronic kidney disease. J Clin Nephrol. 2021;21(07):594\u20138.","journal-title":"J Clin Nephrol."},{"issue":"6","key":"1181_CR69","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.kint.2016.12.021","volume":"91","author":"Y Xie","year":"2017","unstructured":"Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6):1482\u201394.","journal-title":"Kidney Int"},{"issue":"2","key":"1181_CR70","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4103\/1319-2442.284005","volume":"31","author":"H Schiffl","year":"2020","unstructured":"Schiffl H, Al-Nemnem E, Lang SM. Proton-pump inhibitors and chronic kidney disease: hidden consequences of an inappropriate drug use? Saudi J Kidney Dis Transpl. 2020;31(2):312\u20139.","journal-title":"Saudi J Kidney Dis Transpl."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01181-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01181-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01181-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T13:45:59Z","timestamp":1700660759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01181-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1181"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01181-4","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"26 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was financially supported by the University Synergy Innovation Program of Anhui Province (Grant number: GXXT-2021-064), the Enhancement Programme for Basic and Clinical Cooperative Research of Anhui Medical University (Grant number: 2019xkjT016), the Joint Project of Nephrology and Pharmacology at Anhui Medical University (No. 2021cxk012), the Key Project Foundation of Natural Science Research in Universities of Anhui Province in China (No. KJ2021A0329), and the Foundation of Anhui Medical University (No. 2018xkj065).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Xiao Wei, Jun Yu, Zhengkun Xu, Chun Wang, and Yonggui Wu have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"XW, JY, and ZKX contributed to the literature review, data collection, and article writing. JY contributed to the language polishing and graphical drawing (partial figure created with BioRender.com). CW and YGW contributed to the project design and article modification. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}